BXQ-350 Neuroprotective Outcomes in Chemotherapy Induced Peripheral Neuropathy (CIPN) Patients

During Bexion’s Phase 1 study of BXQ-350 in adult patients with advanced solid tumors, a patient self-reported complete resolution of long term, persistent Chemotherapy Induced Peripheral Neuropathy (CIPN).  Due to this unexpected reporting, Bexion elected to explore this finding further by reviewing data from a cohort of patients who had entered the study with peripheral neuropathy, largely due to prior chemotherapy treatments.

Retrospective Analysis of BXQ-350 Phase 1 Data Suggests Clinical Improvement in Peripheral Neuropathy … A Potential Game Changer

CIPN chart

Highlights of Study 1

  • 8 of the 11 (73%) peripheral neuropathy sufferers reported symptom improvement (anecdotal, not primed)
  • Resolution of short-term neuropathy (3 subjects) may have been coincidental to recent termination of offending chemotherapy
  • Diabetic peripheral neuropathy subject: intermittent tingling in fingers became much less frequent
  • 5 of the 6 long-term, persistent peripheral neuropathy subjects improved while on BXQ-350

Tumor Types

  • Pancreatic (5)
  • Colorectal (3)
  • Esophageal (1)
  • GIST (1 ) diabetic
  • Parotid (1)

“Chemotherapy-induced peripheral neuropathy (CIPN) remains an unmet clinical need affecting far too many patients. We are excited to bring into the clinic an exciting new approach incorporating our unique knowledge at the molecular level to treating this important condition, and to potentially treat other forms of neuropathy”

Ray Takigiku, Ph.D. , President and CEO, Bexion Pharmaceuticals
  1. Anecdotal patient reports from clinical study of BXQ-350.AA, in progress. The safety and efficacy of BXQ-350 are current being evaluated in clinical trials.
Neuroprotective Outcomes
Market Opportunity
What is CIPN?
Impact of CIPN